For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of this treatment and Tafamidis meglumine represents a true advancement . These novel therapies stabilize the transthyretin protein, halting its damaging build-up and alleviating the seve